|
1）Gregg BE, Moore PC, Demozay D, et al. Formation of a human β-cell population within pancreatic islets is set early in life. J Clin Endocrinol Metab. 2012; 97: 3197-206
|
|
|
|
2）Bosco D, Armanet M, et al. Unique arrangement of alpha- and beta-cells in human islets of Langerhans. Diabetes. 2010; 59: 1202-10
|
|
|
|
|
|
3）Huang YC, Rupnik MS, Karimian N, et al. In situ electrophysiological examination of pancreatic α cells in the streptozotocin-induced diabetes model, revealing the cellular basis of glucagon hypersecretion. Diabetes. 2013; 62: 519-30
|
|
|
|
|
|
4）Mighiu PI, Yue JT, Filippi BM, et al. Hypothalamic glucagon signaling inhibits hepatic glucose production. Nat Med. 2013; 19: 766-72
|
|
|
|
|
|
5）von Meyenn F, Porstmann T, Gasser E, et al. Glucagon-induced acetylation of Foxa2 regulates hepatic lipid metabolism. Cell Metab. 2013; 17: 436-47
|
|
|
|
|
|
6）Miller RA, Chu Q, Xie J, et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013; 494: 256-60
|
|
|
|
|
|
7）Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest. 2012; 122: 4-12
|
|
|
|
|
|
8）Lee Y, Wang MY, Du XQ, et al. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes. 2011; 60: 391-7
|
|
|
|
|
|
9）Ali S, Lamont BJ, Charron MJ. Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest. 2011; 121: 1917-29
|
|
|
|
|
|
10）Bajorunas DR, Fortner JG, Jaspan JB. Glucagon immunoreactivity and chromatographic profiles in pancreatectomized humans. Diabetes. 1986; 35: 886-93
|
|
|
|
|
|
11）Orskov C, Jeppesen J, Madsbad S, et al. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest. 1991; 87: 415–23
|
|
|
|
|